Comparative Pharmacology
Head-to-head clinical analysis: DAYTRANA versus METADATE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYTRANA versus METADATE ER.
DAYTRANA vs METADATE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their extracellular concentrations.
Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.
Initial: 10 mg transdermal patch applied to hip for 9 hours daily; may titrate weekly in increments of 5 mg to a maximum of 30 mg/day.
Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.
None Documented
None Documented
Terminal half-life in children is approximately 5–6 hours; in adults, approximately 5 hours; wears off within 12 hours of patch removal.
Terminal elimination half-life: 3-6 hours (mean 4.5 hours) for methylphenidate; clinical context: requires multiple daily dosing or extended-release formulation.
Renal (approx. 78% unchanged) and fecal (approx. 10%); remainder as metabolites.
Renal (80% as metabolites, <1% unchanged); fecal (10-20%) via biliary elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant